{
    "nct_id": "NCT03061812",
    "official_title": "A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for Subjects With Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) Who Have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy (TAHOE)",
    "inclusion_criteria": "* Participant must have histologically or cytologically confirmed advanced or metastatic Small Cell Lung Cancer (SCLC) with documented first disease progression during or following front-line platinum-based systemic regimen\n* Tumor must have high Delta-like protein 3 (DLL3) expression defined as having â‰¥ 75% tumor cells staining positive according to the VENTANA DLL3 (SP347) IHC Assay.\n* Participant must have measurable disease, as defined per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n* Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Participant must have recovery to Grade 0 or 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug administration.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participant has a documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association Class (NYHA) III - IV within 6 months prior to their first dose of study drug.\n* Participant has known leptomeningeal metastases.\n* Participant has received more than one prior systemic therapy regimen for SCLC.\n* Participant had a serious infection within 2 weeks prior to randomization, including any Grade 3 or higher viral, bacterial, or fungal infection.\n* Participant has a history of active malignancies other than SCLC within the past 2 years prior to study entry, with the exception of in situ cancer which was curatively treated.\n* Participant had prior exposure to topotecan, irinotecan or any other topoisomerase I inhibitors.",
    "miscellaneous_criteria": ""
}